NEWS

Filter Releases
 
News
Date Title and Summary View
May 12, 2017
FREMONT, Calif., May 12, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today reported positive, topline results from the T3MPO-1 trial, the first of two Phase 3 trials evaluating tenapanor for the treatment of patie...
May 5, 2017
FREMONT, Calif., May 5, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today reported an update on recent progress and financial results for the first quarter ended March 31, 2017. ...
Apr 18, 2017
FREMONT, Calif., April 18, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that it will present clinical and preclinical data during two poster presentations at the following upcoming medical meetings:...
Feb 27, 2017
FREMONT, Calif., Feb. 27, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that Mike Raab, chief executive officer of Ardelyx, will present at the Cowen and Company 37th Annual Healthcare Conference on ...
Feb 17, 2017
FREMONT, Calif., Feb. 17, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardiorenal and gastrointestinal (GI) diseases, today reported recent company progress and financial results for the fourth quarter and full year ended December 31, 2016. ...
Feb 15, 2017
FREMONT, Calif., Feb. 15, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today reported that the Phase 3 clinical trial evaluating the efficacy and safety of tenapanor as a treatment for hyperphosphatemia in patients with...
Jan 3, 2017
FREMONT, Calif., Jan. 3, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced the initiation of a Phase 3 clinical trial and an onset-of-action clinical trial evaluating RDX7675 in patients with hyperkalemia, a poten...
Jan 3, 2017
FREMONT, Calif., Jan. 3, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced that Mike Raab, chief executive officer of Ardelyx, will present a company overview at the J.P. Morgan 35th Annual Healthcare Conference o...
Nov 7, 2016
FREMONT, Calif., Nov. 7, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today reported an update on recent progress and financial results for the third quarter ended September 30, 2016. "We have made substantial progress throughout 2016,...
Oct 31, 2016
FREMONT, Calif., Oct. 31, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that management will host a conference call and audio webcast on Monday, November 7, 2016, at 4:05 p.m. Eastern Time to provide a business update and review th...
Oct 24, 2016
FREMONT, Calif., Oct. 24, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Reginald Seeto, MBBS, has joined the company in the newly created position of chief operating officer. Dr. Seeto brings over a decade of pharmaceutical in...
Oct 19, 2016
FREMONT, Calif., Oct. 19, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the presentation of positive global endpoint data from its Phase 2b trial, completed in September 2014, which evaluated tenapanor for the treatment of patients...
Sep 22, 2016
FREMONT, Calif., Sept. 22, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mark Kaufmann, Chief Financial Officer, will present an overview of the Company during the Ladenburg Thalmann 2016 Healthcare Conference at 9:30 a.m. Eas...
Aug 15, 2016
FREMONT, Calif., Aug. 15, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Mike Raab, President and Chief Executive Officer, will present an overview of the Company during the 2016 Wedbush PacGrow Healthcare Conference at 12:45 p...
Aug 8, 2016
FREMONT, Calif., Aug. 8, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2016. "2016 continues to be a momentous year," said Mike Raab, President and Chief Executive ...
Page:
...
Next Last
 
= add release to Briefcase

RESOURCES